title: Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)
abstract: BACKGROUND
  The subjective and reinforcing effects of cocaine in humans are associated with the enhancement of endogenous dopamine function in the mesolimbic system. This study examined the role of dopamine D1-like receptors in the behavioral and mood effects of cocaine by evaluating the effects of the selective D1/D5 antagonist ecopipam (SCH 39166) on subjective responses to intravenous cocaine in 11 subjects with cocaine dependence as defined by DSM-IV.
  
  
  METHODS
  Subjects were pretreated in a randomized double-blind fashion with either placebo or 10 mg, 25 mg, or 100 mg of ecopipam orally on 4 separate occasions. Two hours later a single intravenous injection of 30 mg of cocaine was administered. Subjective and cardiovascular responses were measured and blood samples for pharmacokinetic evaluation were obtained prior to cocaine dosing and at various times after dosing.
  
  
  RESULTS
  The euphoric (P = .004) and stimulating (P = .03) effects of cocaine were attenuated in a dose-dependent manner by ecopipam, while ratings of desire to take cocaine were diminished (P = .02). Ecopipam in combination with cocaine was safe and well tolerated.
  
  
  CONCLUSIONS
  These data indicate a potentially important role for D1-like receptors in the acute mood-altering and rewarding effects of cocaine in humans.
authors.affiliation: Psychopharmacology and Dependence Research Unit, Centre for Research in Women's Health, Sunnybrook and Women's College Health Sciences Centre, Women's College Campus, Toronto, Ontario, Canada. myroslava.romach@utoronto.ca
authors.forename: M K
authors.initials: MK
authors.lastname: Romach
authors.forename: P
authors.initials: P
authors.lastname: Glue
authors.forename: K
authors.initials: K
authors.lastname: Kampman
authors.forename: H L
authors.initials: HL
authors.lastname: Kaplan
authors.forename: G R
authors.initials: GR
authors.lastname: Somer
authors.forename: S
authors.initials: S
authors.lastname: Poole
authors.forename: L
authors.initials: L
authors.lastname: Clarke
authors.forename: V
authors.initials: V
authors.lastname: Coffin
authors.forename: J
authors.initials: J
authors.lastname: Cornish
authors.forename: C P
authors.initials: CP
authors.lastname: O'Brien
authors.forename: E M
authors.initials: EM
authors.lastname: Sellers
mesh_terms: D000328:Adult; D016739:Behavior, Addictive / Q000517:prevention & control / Q000523:psychology; D001552:Benzazepines / Q000494:pharmacology* / Q000627:therapeutic use; D003042:Cocaine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D019970:Cocaine-Related Disorders / Q000503:physiopathology / Q000517:prevention & control / Q000523:psychology*; D018492:Dopamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D005059:Euphoria / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012201:Reward
chemical_list: D001552:Benzazepines; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; C058081:ecopipam; D003042:Cocaine